Literature DB >> 17035319

Epstein-barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity.

Mark Rovedo1, Richard Longnecker.   

Abstract

Latent membrane protein 2A (LMP2A) and LMP2B are viral proteins expressed during Epstein-Barr virus (EBV) latency in EBV-infected B cells both in cell culture and in vivo. LMP2A has important roles in modulating B-cell receptor (BCR) signal transduction by associating with the cellular tyrosine kinases Lyn and Syk via specific phosphotyrosine motifs found within the LMP2A N-terminal tail domain. LMP2A has been shown to alter normal BCR signal transduction in B cells by reducing levels of Lyn and by blocking tyrosine phosphorylation and calcium mobilization following BCR cross-linking. Although little is currently known about the function of LMP2B in B cells, the similarity in structure between LMP2A and LMP2B suggests that they may localize to the same cellular compartments. To investigate the function of LMP2B, B-cell lines expressing LMP2A, LMP2B, LMP2A/LMP2B, and the relevant vector controls were analyzed. As was previously shown, cells expressing LMP2A had a dramatic block in normal BCR signal transduction as measured by calcium mobilization and tyrosine phosphorylation. There was no effect on BCR signal transduction in cells expressing LMP2B. Interestingly, when LMP2B was expressed in conjunction with LMP2A, there was a restoration of normal BCR signal transduction upon BCR cross-linking. The expression of LMP2B did not alter the cellular localization of LMP2A but did bind to and prevent the phosphorylation of LMP2A. A restoration of Lyn levels, but not a change in LMP2A levels, was also observed in cells coexpressing LMP2B with LMP2A. From these results, we conclude that LMP2B modulates LMP2A activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17035319      PMCID: PMC1797235          DOI: 10.1128/JVI.01302-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  100 in total

1.  Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells.

Authors:  Donna Hochberg; Tatyana Souza; Michelle Catalina; John L Sullivan; Katherine Luzuriaga; David A Thorley-Lawson
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 2.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas.

Authors:  David A Thorley-Lawson; Andrew Gross
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

3.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals.

Authors:  R G Caldwell; J B Wilson; S J Anderson; R Longnecker
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

4.  The pituitary-specific transcription factor GHF-1 is a homeobox-containing protein.

Authors:  M Bodner; J L Castrillo; L E Theill; T Deerinck; M Ellisman; M Karin
Journal:  Cell       Date:  1988-11-04       Impact factor: 41.582

5.  A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-kappa B, and stress-activated protein kinase.

Authors:  E Hatzivassiliou; W E Miller; N Raab-Traub; E Kieff; G Mosialos
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

6.  An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase.

Authors:  R Longnecker; B Druker; T M Roberts; E Kieff
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

7.  Distinct p53/56lyn and p59fyn domains associate with nonphosphorylated and phosphorylated Ig-alpha.

Authors:  C M Pleiman; C Abrams; L T Gauen; W Bedzyk; J Jongstra; A S Shaw; J C Cambier
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

8.  Epstein-Barr virus (EBV) LMP2A alters normal transcriptional regulation following B-cell receptor activation.

Authors:  Toni Portis; Richard Longnecker
Journal:  Virology       Date:  2004-01-20       Impact factor: 3.616

9.  Epstein-Barr virus latent membrane protein 2A regulates c-Jun protein through extracellular signal-regulated kinase.

Authors:  Shao-Yin Chen; Jean Lu; Yin-Chu Shih; Ching-Hwa Tsai
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Latent infection membrane protein transmembrane FWLY is critical for intermolecular interaction, raft localization, and signaling.

Authors:  Teruhito Yasui; Micah Luftig; Vishal Soni; Elliott Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

View more
  20 in total

1.  EBV noncoding RNA binds nascent RNA to drive host PAX5 to viral DNA.

Authors:  Nara Lee; Walter N Moss; Therese A Yario; Joan A Steitz
Journal:  Cell       Date:  2015-02-05       Impact factor: 41.582

2.  Minimal protein domain requirements for the intracellular localization and self-aggregation of Epstein-Barr virus latent membrane protein 2.

Authors:  Monica Jo Tomaszewski-Flick; David T Rowe
Journal:  Virus Genes       Date:  2007-06-13       Impact factor: 2.332

Review 3.  The molecular march of primary and recurrent nasopharyngeal carcinoma.

Authors:  Nicholas J Campion; Munira Ally; Bernhard J Jank; Jahangir Ahmed; Ghassan Alusi
Journal:  Oncogene       Date:  2021-01-21       Impact factor: 9.867

4.  A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.

Authors:  Christopher P Fox; Tracey A Haigh; Graham S Taylor; Heather M Long; Steven P Lee; Claire Shannon-Lowe; Simon O'Connor; Catherine M Bollard; Javeed Iqbal; Wing C Chan; Alan B Rickinson; Andrew I Bell; Martin Rowe
Journal:  Blood       Date:  2010-07-29       Impact factor: 22.113

5.  Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection.

Authors:  Markus P Rechsteiner; Christoph Berger; Ludwig Zauner; Jürg A Sigrist; Matthias Weber; Richard Longnecker; Michele Bernasconi; David Nadal
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

6.  Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus.

Authors:  Mohsen Navari; Fabio Fuligni; Maria A Laginestra; Maryam Etebari; Maria R Ambrosio; Maria R Sapienza; Maura Rossi; Giulia De Falco; Davide Gibellini; Claudio Tripodo; Stefano A Pileri; Lorenzo Leoncini; Pier P Piccaluga
Journal:  Front Microbiol       Date:  2014-12-23       Impact factor: 5.640

Review 7.  Understanding the interplay between host immunity and Epstein-Barr virus in NPC patients.

Authors:  Yong Shen; Suzhan Zhang; Ren Sun; Tingting Wu; Jing Qian
Journal:  Emerg Microbes Infect       Date:  2015-03-25       Impact factor: 7.163

Review 8.  Epstein-Barr virus latent genes.

Authors:  Myung-Soo Kang; Elliott Kieff
Journal:  Exp Mol Med       Date:  2015-01-23       Impact factor: 8.718

9.  The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation.

Authors:  K M Shah; S E Stewart; W Wei; C B J Woodman; J D O'Neil; C W Dawson; L S Young
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

10.  The effect of Epstein-Barr virus Latent Membrane Protein 2 expression on the kinetics of early B cell infection.

Authors:  Laura R Wasil; Monica J Tomaszewski; Aki Hoji; David T Rowe
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.